Fluorescent method for chemotherapy efficiency prediction in children with acute lymphoblastic leukemia by determination of adenosine triphosphate concentrations in mitochondria

FIELD: medicine.

SUBSTANCE: invention relates to the fluorescent method for chemotherapy efficiency prediction in children with acute lymphoblastic leukemia by determining the ATP concentrations in mitochondria, for which blood sampling is performed before and after chemotherapy, a fluorescent macro biomarker of chemotherapy efficiency is isolated, where macro biomarker is the ATP concentration in blood cells mitochondria, which is determined automatically, using a laser confocal microscope, through macro biomarker fluorescence intensity recording.

EFFECT: invention provides assessment of chemotherapy efficiency, in particular the emergence of hepatotoxic effects and drug resistance during chemotherapy in children with acute lymphoblastic leukemia.

1 ex

 



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention represents a method for assessing a probability of progression of the clinical course of oral lichen planus in the patients with hypercholesterolemia and hepatobiliary disorders.

EFFECT: invention represents developing criteria for assessing a probability of progression of the clinical course of oral lichen planus in the patients with hypercholesterolemia and hepatobiliary disorders.

4 ex, 3 tbl

FIELD: medicine.

SUBSTANCE: technique involves performing clinical laboratory blood analysis, measuring neutrophil, lymphocyte, thrombocyte and erythrocyte acid phosphatase activity; an integral diagnostic index of lysosomal blood activity is calculated by the presented formula. If the integral diagnostic index of lysosomal blood activity exceeds 26.2 activity units, the electromagnetic body exposure is diagnosed; if the above index is less than 26.2 activity units, the negative body response to the exposure is concluded.

EFFECT: invention enables providing the more reliable diagnosis of the electromagnetic exposure by the integral evaluation of lysosomal activity in all blood cell types that is of high importance for working capacity examination and employment assistance resolution.

3 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: chronic infectious-inflammatory diseases (CIIDs) are diagnosed. Clinical blood analysis and bacteriological tests are conducted. A sensibilisation index (SI) and an immune responsiveness index (IRI) are calculated; total microbial count per 1 m3 of the working space air is measured, and the total microbial number (TMN) is derived. If the TMN is less than 500 CFU/m3 with no CIIDs diagnosed accompanied by the SI of less than 1.08 standard units and the IRI of less than 13 standard units, the immunoassay is considered to be inadvisable. If the TMN falls within the range of 500-2,500 CFU/m3 with one CIID diagnosed accompanied by the SI from 1.08 to 1.3 standard units and the IRI from 13.1 to 15.7 standard units, the immunoassay with the first-level tests seems advisable. Whereas the TMN exceeding 2,500 CFU/m3 with at least two CIIDs accompanied by the SI of 1.4-1.5 standard units and the IRI of 15.8-18.3 standard units, the immunoassay with the second-level tests is thought expedient.

EFFECT: invention enables detecting the workers in need of further examination for the purpose of timely immune correction in the setting of mass routine examinations.

1 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: senior guinea pigs are exposed to optical light generated by light emitting diodes or fluorescent tubes at a colour temperature of 4,500 K within the wavelength region of 360-460 nm for various time distances. The exposure is assessed by functional activity indices of neutrophilic granulocytes and a mononuclear cell count.

EFFECT: using the method requires no expensive equipment, critical chemicals; it is of a particular importance for evaluating the biological safety of new artificial light sources embedded into a light-colour medium; it provides expanded information on biological effects of optical light.

3 tbl

FIELD: medicine.

SUBSTANCE: invention relates to laboratory diagnostics, namely to a method for the preservation of protein of urine, sampled for the diagnostics of infectious haemorrhagic fever with renal syndrome (HFRS) by PCR method. The essence of the method consists in the following: urine is sampled from a patient in an acute period of a disease, the protein is separated, precipitated by a method of salting-out with ammonium sulphate with its further drying and preservation at a temperature of 20-24°C. Diagnostics by means of PCR method is carried out after salt removal by a method of dialysis with flowing water for 24-48 hours of a mass, obtained by mixing 3-5 g of the dry protein and 8-12 ml of distilled water.

EFFECT: application of the claimed method makes it possible to realise HFRS diagnostics after many years with the application of urine protein, preserved in a dry form.

1 dwg, 1 ex

FIELD: medicine.

SUBSTANCE: method involves measuring blood leukocytes, blood leukocyte shift index (BLSI), neutrophil/lymphocyte ratio (NLR), leukocytal intoxication index (LII). If observing BLSI >4, NLR >5, LII >4 and detecting TNFα G-308A gene mutation, an increasing intensity of a systemic inflammatory reaction is predicted in the given category of patients.

EFFECT: using the given method enables predicting a degree of the intensity of the systemic inflammatory reaction in geriatric patients suffering from acute myocardial infarction, performing primary prevention in the patients with TNFα G-308A polymorphism detected and the positive medical history of the ischemic heart disease, as well as the secondary prevention of the complicated acute myocardial infarction.

3 ex

FIELD: medicine.

SUBSTANCE: method involves analysing the newborn's clinical and functional health indicators, namely the ventilation parameters: fractional oxygen concentration in the inhaled mixture, mean airway pressure, partial oxygen pressure in the arterial postductal blood, and calculating an oxygenation index. If the oxygenation index is 3.5 or less, non-invasive pulmonary ventilation is considered to be effective, whereas the oxygenation index of more than 3.5 shows therapeutic ineffectiveness.

EFFECT: method enables predicting a success rate of various techniques for non-invasive pulmonary ventilation in premature newborns with a very low and extremely low birth body weight diagnosed with respiratory distress syndrome.

2 ex

FIELD: medicine.

SUBSTANCE: method involves analysing the newborn's clinical and functional health indicators, namely the ventilation parameters: fractional oxygen concentration in the inhaled mixture, mean airway pressure, partial oxygen pressure in the arterial postductal blood, and calculating an oxygenation index. If the oxygenation index is 3.5 or less, non-invasive pulmonary ventilation is considered to be effective, whereas the oxygenation index of more than 3.5 shows therapeutic ineffectiveness.

EFFECT: method enables predicting a success rate of various techniques for non-invasive pulmonary ventilation in premature newborns with a very low and extremely low birth body weight diagnosed with respiratory distress syndrome.

2 ex

FIELD: medicine.

SUBSTANCE: patient's pre-operative health is assessed with taking into account the presence/absence of pulmonary and renal diseases, erythrocyte Rh C-antigen, hyperinosemia of more than 4 g/l and erythrocyte count of 4.81×1012/l and less; a haemolytic perfusion risk (HPR) is calculated by formula HPR=(6.38×Xpulm+8.93×Xhyp+3.32×XEr)-(4.10×Xren+2.95×XC), wherein the numerical values 6.38; 8.93; 3.32; 4.10; 2.95 are coefficients; Xpulm is the presence (1)/absence (0) of pulmonary diseases; Xhyp is the presence (1)/absence (0) of pre-operative hyperinosemia; XEr is the presence (1)/absence (0) of the pre-operative erythrocyte count 4.81×1012/l and less; Xren is the presence (1)/absence (0) of renal diseases; XC is the presence (1)/absence (0) of erythrocyte Rh C-antigen; if HPR>6.1, pronounced erythrocyte lysis is predicted; HPR<6.1 shows moderate erythrocyte lysis.

EFFECT: method enables increasing accuracy, information value and accessibility of the erythrocyte lysis prediction.

2 ex, 1 dwg, 3 tbl

FIELD: biotechnologies.

SUBSTANCE: invention can be used for determination of atherogenicity of immune complexes containing multiply modified low density lipoproteins (IC-MMLDLP). For this purpose basic calcium superphosphate of IC-MMLDLP is prepared from human blood serum by treatment with the buffer containing 10% solution of polyethyleneglycol with a molecular weight 3350 (PEG-3350), in the ratio 1:2.5, then it is incubate within 10 minutes at a room temperature. IC-MMLDLP aggregates are pelleted, dissolved in the buffer without PEG-3350, analysed for the content of cholesterol in immune complexes (ChIK) and the level of guinea pig complement binding (EBC) by precipitated immune complexes. IC-MMLDLP atherogenicity is calculated as SSK to HIK ratio. If the value is below 24 units a high blood atherogenicity because of the reduced complement activating IgG function in IC-MMLDLP is stated.

EFFECT: method allows to assess IC-MMLDLP atherogenicity, diagnose atherosclerosis at a preclinical stage, and also to predict both the course of atherosclerotic process at individuals, and efficiency of the conducted therapy.

1 tbl

FIELD: medicine.

SUBSTANCE: invention relates to laboratory methods for blood analysis. Plasma is dropped in copper sulfate solution with density 1.023 g/cm3, not above, and time for drop falling on bottom of graduated cylinder with column height 243 mm is measured. The blood plasma density value is calculated by the formula:

wherein is the unknown blood plasma density (g/cm3); is copper sulfate solution density measured by areometer (g/cm3); t is average falling time of plasma drop in the copper sulfate solution (as seconds); 0.260130126 and 0.00290695 are correction coefficients. Temperature of plasma and copper sulfate solution is 20oC. Method is simple and suitable and allows carrying out analysis of small volumes of blood plasma and to reduce analysis time.

EFFECT: improved assay method.

2 ex

FIELD: medicine.

SUBSTANCE: method involves carrying out microscopic examination of blood serum samples taken from femoral vein and cubital vein. Femoral vein sample is taken on injured side. The examination is carried out before and after treatment. The blood serum samples are placed on fat-free glass slide in the amount of 0.01-0.02 ml as drops, dried at 18-30°C for 18-24 h. The set of pathological symptoms becoming larger or not changed after the treatment in comparison to sample taken before treatment, and morphological picture of samples under comparison taken from the cubital vein showing no changes or being changed to worse, the treatment is considered to be effective.

EFFECT: enabled medicamentous treatment evaluation in course of treatment to allow the treatment mode to be changed in due time; avoided surgical intervention (amputation); retained active life-style of aged patients.

4 dwg

FIELD: medicine, obstetrics, gynecology.

SUBSTANCE: in the first trimester of pregnancy one should study the content of CD8+CD11b lymphocytes and at their values being either equal or above 2% it is possible to predict gestosis. The present innovation enables to choose correct tactics of treating pregnant women that, in its turn, leads to decreased frequency of this complication of pregnancy and the risk for the development of fetal and neonatal pathology.

EFFECT: higher accuracy of prediction.

3 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: the present innovation deals with studying and treating diseases of inflammatory, autoimmune and degenerative genesis. One should perform sampling of heparinized blood followed by its sedimentation to obtain blood plasma with leukocytes and centrifuging to isolate the latter which are washed against erythrocytic and serumal admixtures, and, also, it deals with calculating the number of cells in samples out of leukocytic suspension after incubation (B) for 1.5 h at 37 C in holes of plastic microplotting board, out of leukocytic suspension one should additionally prepare two samples, one should be applied to calculate total number of leukocytes before incubation (A), the second sample undergoes incubation at the same mode at addition of autoserum to calculate the number of cells remained after incubation (C). One should state upon adhesive properties of leukocytes by the index of spontaneous adhesion (D), where D=(A-B)/B.100%, and effect for enhanced cellular adhesion under the impact of autoserum should be detected by the value of K=(B-C)/C.100% at K ≥ 30%, where B - C - the number of cells undergone additional adhesion after addition of autoserum. The present innovation widens functional possibilities of the suggested method due to obtaining additional values depicting adhesive properties of blood leukocytes.

EFFECT: higher accuracy of detection.

FIELD: medicine, diagnostics.

SUBSTANCE: the present innovation deals with blood sampling, separating plasma against erythrocytes, moreover, in plasma on should detect activity of antithrombin III, proteins C and S, XIIa-dependent fibrinolysis and concentration of plasminogen obtained results should be expressed as relative units followed by calculating integral parameter that characterizes the state of anticoagulant-fibrinolytic potential (IPAFP) by the following formula: IPAFP = [(C1 + C2)/(C3 + C4)] x 100, where C1 - the ratio of observed value of antithrombin III activity to the value of inferior border of the range of analogous parameter norm; C2 - the ratio of observed value for the activity of proteins C and S system to the value of inferior border of the range of this parameter norm; C3 - the ratio of the value of inferior border of plasminogen concentration under normal conditions to observed value of analyzed parameter; C4 - coefficient calculated with the help of regression equation: C4 = 0.9 + (0.01 x X), where X - terms of lysis of patient's euglobulin clot/min, and at IPAFP value of 101.4 U and higher one should state anticoagulant-fibrinolytic blood potential to be in norm, in interval of 64.8 - 101.3 -as insufficient, and at 64.7 and below - as critical. The present method simplifies the procedure of evaluating the state of endogenous anticoagulants and activity of XIIa-dependent fibrinolysis.

EFFECT: increased diagnostic value of obtained results.

3 ex, 1 tbl

FIELD: medicine, laboratory diagnosis.

SUBSTANCE: method involves determination of the patient blood content of globulin-alpha 1, globulin-beta, globulin-gamma and the total bilirubin content followed by calculation of diagnosis indices for the patient (Y1, Y2, Y3) by using the computer program "Statistica 1.5" and introducing values X1, X2, X3 and X4 in computer wherein X1 means globulin-alpha 1 value; X2 means globulin-beta value; X3 means globulin-gamma value; X4 means total bilirubin value. Obtained values of diagnosis indices for the individual patient (Y1, Y2, Y3) are compared with average values of diagnosis indices (Y1', Y2', Y3') for different urogenital infections followed by comparison by sign and value. By the maximal coincidence of diagnosis index values for the individual patient with average diagnosis index values urogenital disease is diagnosed and the following diagnosis index average values are used: for chlamydiosis: Y1' = -2; Y2' = -0.1; Y3' = -0.2; for mycoplasmosis: Y1' = 2; Y2' = 0.8; Y3' = -0.04; for ureaplasmosis: Y1' = 2; Y2' = -1; Y3' = 0.02; for health persons: Y1' = -2; Y2' = 0.1; Y3' = 0.2. Invention provides the development of a method for express-diagnosis of infection at initial stage and diagnosis of atypical forms that occur in these diseases, and differential diagnosis of chlamydiosis, mycoplasmosis and ureaplasmosis. Invention can be used for carrying out the differential diagnosis of chlamydiosis, mycoplasmosis and ureaplasmosis.

EFFECT: improved method for express-diagnosis.

2 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: method involves determining absolute value of ratio between lymphocyte number and absolute value of monocyte number in peripheral blood at the end of combine radiation therapy. The ratio is divided by 4.05. The result value being greater than 1, no disease relapse occurrence is predicted during the first observation year. The value being less than 1, tumor growth progress is stated and carcinoma relapse is predicted at the first year after treatment.

EFFECT: enhanced accuracy in detecting pathological process progress before observing clinical manifestations.

1 tbl

FIELD: medicine.

SUBSTANCE: method involves determining infrared radiation absorption coefficient in blood plasma in bandwidth of 1543-1396 cm-1. The infrared radiation absorption coefficient is determined in %. The value being equal to 29.7±1.1%, catarrhal cholecystitis is diagnosed. The value being 26.4±1.4%, phlegmonous cholecystitis is diagnosed. The value being 21.2±1.8%, gangrenous cholecystitis is diagnosed. The value being equal to 18.6±0.5%, gangrenous perforated cholecystitis case is diagnosed. The value in norm is equal to 32.4±0.8%.

EFFECT: high accuracy and specificity of diagnosis.

FIELD: biomedicine.

SUBSTANCE: the present innovation deals with biomedical measuring technologies, in particular, to those to detect bactericide activity of blood serum according to the level of its inhibiting impact upon luminescence intensity of sulfur-sensitive luminescent bacteria (ΣimpO) against control - luminescence intensity the same sulfur-sensitive luminescent bacteria that had no contact with blood serum (ΣimpK), then one should calculate the value of bactericide activity of blood serum by the following formula:

As sulfur-sensitive luminescent bacteria one should apply either natural or recombinant microorganisms being characterized by direct proportionality between intensity of decreased spontaneous bioluminescence level and degree of bactericide effect. For example, it is possible to apply Escherichia coli strain with genes of Photobacterium leiognathi luminescent system. The suggested method enables to shorten the duration for detecting bactericide activity of blood serum and decrease its labor intensity.

EFFECT: higher efficiency of detection.

1 cl, 1 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: method involves determining blood insulin I and thyroxin T content and phagocytic leukocyte activity (PLA). Activity coefficient is calculated on the basis of formula KA=IxPLA/T. KA value being found greater than 2.8 units, considerable amelioration treatment effect is predicted. The value being from 1.4 to 2.8 units, amelioration is predicted. KA being less than 1.4 units, lower treatment efficiency is predicted.

EFFECT: high reliability of prognosis.

Up!